FDA Alerts

FDA approves fezolinetant for vasomotor symptoms caused by menopause

Astellas Pharma's drug, Veozahtm (fezolinetant), has been approved by the FDA for the treatment of moderate to severe vasomotor symptoms (VMS) caused by menopause. It is the first nonhormonal neurokinin 3 (NK3) receptor antagonist to receive approval for this indication. "Today's approval of fezolinetant is a significant and, I believe,...